At a press conference during the ASCO 2012 Annual Meeting in Chicage, June 1st - June 4th, Dr Hope Rugo presents results from a phase III randomised trial that found weekly administration of either of two newer and significantly more costly agents, nanoparticle albumin bound (“nab”) paclitaxel (Abraxane) and ixabepilone (Ixempra), was not superior to standard weekly dosing of paclitaxel as first-line therapy for locally advanced or metastatic breast cancer.